Vogtino M 500mg/0.3mg Tablet SR
Marketer
Roma Pharma Pvt Ltd
Salt Composition
Metformin (500mg) + Voglibose (0.3mg)
Overview Vogtino M 500mg/0.3mg Tablet SR
Diabeva 500mg/0.3mg Extended-Release Tablets are classified as antidiabetic agents. This dual-action medication manages type 2 diabetes in adults by regulating blood glucose. Diabeva should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial, even with well-controlled blood sugar, as abrupt cessation can elevate glucose levels, potentially leading to complications like kidney impairment, vision loss, neuropathy, and limb amputation. This medication is part of a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your healthcare provider. Lifestyle modifications are vital for diabetes control. Potential side effects include nausea, altered taste, appetite changes, gas, abdominal discomfort, diarrhea, and skin reactions. These are usually transient and self-limiting; however, persistent or concerning effects warrant medical attention. Your physician can offer strategies to manage or alleviate side effects. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their doctor before commencing treatment. Pregnant or lactating women must consult their physician prior to use. Regular blood glucose monitoring is essential, and your doctor may order blood tests to assess blood cell counts and liver function.
Primary Ingredients of Vogtino M 500mg/0.3mg Tablet SR
No text provided. Please provide the text you wish me to rewrite.
Uses of Vogtino M 500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Vogtino M 500mg/0.3mg Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Swallow the Vogtino M 500mg/0.3mg Tablet SR whole; do not damage the tablet by chewing, crushing, or breaking it. Administer this medication with a meal.
Common Side effects of Vogtino M 500mg/0.3mg Tablet SR:
- Flatulence
- Diarrhea
- Abdominal pain
- Vomiting
- Decreased appetite
How to use Vogtino M 500mg/0.3mg Tablet SR:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Vogtino M 500mg/0.3mg Sustained-Release Tablet should be administered with a meal.
How Vogtino M 500mg/0.3mg Tablet SR works:
Vogtino M 500mg/0.3mg sustained-release tablets contain a dual antidiabetic formulation.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use and Vogtino M 500mg/0.3mg Tablet SR is contraindicated.
PregnancyCONSULT YOUR DOCTOR
The extended-release Vogtino M 500mg/0.3mg tablet may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescription. Physician consultation is recommended.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Vogtino M 500mg/0.3mg tablets are likely unsuitable for use while breastfeeding. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Extended-release Vogtino M 500mg/0.3mg tablets typically do not impair driving ability. Nevertheless, individuals taking this medication concurrently with other antidiabetic medications, including sulfonylureas, insulin, or repaglinide, should be aware of the potential for low blood sugar.
KidneyCAUTION
Exercise caution when administering Vogtino M 500mg/0.3mg SR tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Vogtino M 500mg/0.3mg SR tablets are contraindicated in patients with severe kidney disease. Close monitoring of kidney function is recommended during treatment.
LiverCONSULT YOUR DOCTOR
Data regarding the use of Vogtino M 500mg/0.3mg sustained-release tablets in individuals with hepatic impairment is scarce. Physician consultation is advised.
What if you forget to take Vogtino M 500mg/0.3mg Tablet SR :
Should you forget a dose of Vogtino M 500mg/0.3mg Extended-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Vogtino M 500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently